ASCO 2021 | Association between TI and improved OS in myelofibrosis patients receiving momelotinib

Srdan Verstovsek, MD, The University of Texas MD Anderson Cancer Center, Houston, TX discusses the association of transfusion independence (TI) with improved overall survival in myelofibrosis (MF) patients receiving momelotinib. Momelotinib exhibits clinical activity against hallmark features of myelofibrosis in myelofibrosis patients. This have been shown by SIMPLIFY-1 (S1) (NCT01969838) and SIMPLIFY-2 (S2) (NCT02101268) clinical trials. S1 enrolled JAK inhibitor-naïve myelofibrosis patients and S2 enrolled myelofibrosis patients with hematological toxicity during prior ruxolitinib therapy. In S1, the momelotinib arm achieved higher TI rates than the ruxolitinib arm; in S2 the momelotinib arm achieved higher TI rates than the best available therapy arm. In both S1 and S2, TI responders in the momelotinib groups showed an overall survival (OS) advantage compared to TI non-responders. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.